This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Between 3,000 and 7,000 infants develop chronic lung disease (CLD) each year in the United States following premature delivery. Prolonged duration of assisted ventilation because of respiratory failure is associated with an increased mortality rate. Thus, any adjunctive therapy, which produces improvement in pulmonary gas exchange in early CLD, should reduce dependency on assisted ventilation and elevated inspired oxygen, and reduce morbidity. Inhaled nitric oxide (INO) has been demonstrated to improve oxygenation in multiple clinical trials in infants with pulmonary hypertension. Preliminary results suggest that INO will improve oxygenation in preterm infants allowing weaning from assisted ventilation and inspired oxygen. This randomized multicenter, placebo-controlled trial of low dose INO will assess the beneficial effect of INO on early CLD.
Showing the most recent 10 out of 563 publications
